Abstract:T-cells genetically engineered to express a chimeric antigen receptor (CAR) have shown remarkable results in patients with B-cell malignancies, including B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma, with some promising efficacy in patients with multiple myeloma. However, the efficacy of CAR T-cell therapy is still hampered by local immunosuppression and significant toxicities, notably cytokine release syndrome (CRS) and neurotoxicity. The tumor microenvironment (TME) has been identified to play a major role in preventing durable responses to immunotherapy in both solid and hematologic malignancies, with this role exaggerated in solid tumors. The TME comprises a diverse set of components, including a heterogeneous population of various cells and acellular elements that collectively contribute towards the interplay of pro-immune and immunosuppressive signaling. In particular, macrophages, myeloid-derived suppressor cells, regulatory T-cells, and cell-free factors such as cytokines are major contributors to local immunosuppression in the TME of patients treated with CAR T-cells. In order to create a more favorable niche for CAR T-cell function, armored CAR T-cells and other combinatorial approaches are being explored for potential improved outcomes compared to conventional CAR T-cell products. While these strategies may potentiate CAR T-cell function and efficacy, they may paradoxically increase the risk of adverse events due to increased pro-inflammatory signaling. Herein, we discuss the mechanisms by which the TME antagonizes CAR T-cells and how innovative immunotherapy strategies are being developed to address this roadblock. Furthermore, we offer perspective on how these novel approaches may affect the risk of adverse events, in order to identify ways to overcome these barriers and expand the clinical benefits of this treatment modality in patients with diverse cancers. Precise immunomodulation to allow for improved tumor control while simultaneously mitigating the toxicities seen with current generation CAR T-cells is integral for the future application of more effective CAR T-cells against other malignancies.

Sensitizing solid tumors to respond to Cytokine-induced apoptosis and CAR T-cell therapy.

Optimising CAR T therapy for the treatment of solid tumors

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

Advancing CAR T-Cell Therapy: Simultaneously Attack Tumor and Immunosuppressive Cells in the Tumor Microenvironment

Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

CAR T cells in solid tumors: challenges and opportunities

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel

Current Clinical Application of the CAR-T Cell Therapy

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors

Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

New insights into CAR T cell-mediated killing of tumor cells

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies

Chimeric antigen receptor dendritic cells targeted delivery of a single tumoricidal factor for cancer immunotherapy

Recent Advances in CAR-Based Solid Tumor Immunotherapy

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment

Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells

Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment